Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats
Table 2
Effect of atorvastatin treatment on lipid parameters of various biological samples after 24 days in adenine-induced CKD rats.
CLT
CKD
CKD + ATV
Serum total cholesterol (mg/dL)
82.11 ± 8.38
153.28 ± 4.64
97.30 ± 11.32
Serum LDL cholesterol (mg/dL)
32.97 ± 14.41
115.28 ± 5.23
60.56 ± 13.08
Serum VLDL cholesterol (mg/dL)
13.72 ± 0.76
21.84 ± 0.34
14.02 ± 1.94
Serum HDL cholesterol (mg/dL)
35.42 ± 3.10
16.16 ± 3.33
22.08 ± 2.80ns
Serum triglycerides (mg/dL)
68.59 ± 3.82
109.19 ± 1.71
70.09 ± 9.71
Serum NEFA (μEq/L)
872.63 ± 18.03
1099.16 ± 16.36
767.41 ± 92.22
Atherogenic index
1.31 ± 0.17
10.63 ± 2.28
3.88 ± 0.93
Coronary risk index
2.31 ± 0.17
11.63 ± 2.28
4.88 ± 0.93
Liver cholesterol (mg/g of liver)
0.38 ± 0.07
4.95 ± 1.30
2.42 ± 0.44
Liver triglycerides (mg/g of liver)
2.55 ± 0.73
10.51 ± 1.39
4.09 ± 1.32
Liver NEFA (mg/g of kidney)
0.73 ± 0.05
1.20 ± 0.06
0.97 ± 0.15ns
Total faecal lipid (mg/g of dried faeces)
44.82 ± 3.9
51.33 ± 7.80
46.33 ± 0.63ns
Faecal cholesterol (mg/g of dried faeces)
1.33 ± 0.16
2.21 ± 0.66
2.26 ± 0.22ns
Faecal triglyceride (mg/g of dried faeces)
3.21 ± 0.33
3.71 ± 0.53
3.24 ± 0.15ns
Total bile acid (μmol/g of dried faeces)
46.23 ± 1.42
52.13 ± 6.25
54.30 ± 5.86ns
Values represent the mean ± SEM of 5 to 6 rats (n = 5 to 6). Significant difference from control: and . Significant difference from CKD: and . No significant difference from CKD: ns; CLT: control; CKD: chronic kidney disease.
